Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brian Cronk

Physician Assistant, Medical Fort Collins, CO Physician Assistant

NPI 1760583785 CMS profile 11105516

3702 S Timberline Rd, Fort Collins, CO 80525

Open in the dashboard

General payments

$10,868

510 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Cronk of Fort Collins, CO is reported in the CMS Open Payments database as having received $10,868 across 510 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,127 137
2024 General $3,497 158
2023 General $2,420 119
2022 General $1,597 82
2021 General $228 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Cronk
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Brian Cronk were reported at $3,127. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Brian Cronk Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $228 $156 $41–$563 $132
2022 $1,597 $185 $55–$649 $149
2023 $2,420 $199 $58–$717 $160
2024 $3,497 $206 $62–$740 $164
2025 $3,127 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,263 112 payments
  2. Gilead Sciences, Inc. $1,349 54 payments
  3. Janssen Biotech, Inc. $1,128 48 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $998 47 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $714 38 payments
  6. Regeneron Healthcare Solutions, Inc. $550 23 payments
  7. Ardelyx, Inc. $536 19 payments
  8. Genzyme Corporation $479 20 payments
  9. Celgene Corporation $427 27 payments
  10. Lilly USA, LLC $365 13 payments
  11. Other $2,057 109 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,660 503 payments
  2. Education $208 7 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $998 52 payments
  2. STELARA $703 30 payments
  3. XIFAXAN $699 37 payments
  4. ENTYVIO $669 31 payments
  5. LINZESS $590 27 payments
  6. IBSRELA $536 19 payments
  7. SKYRIZI $533 28 payments
  8. DUPIXENT $449 19 payments
  9. ZEPOSIA $446 28 payments
  10. TREMFYA $426 18 payments
  11. Other $5,210 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,062

Median for Physician Assistant: 241

Drug cost

$766,665

Median for Physician Assistant: $4,110

Branded share of claims

41.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $300,491
Creon Lipase/Protease/Amylase Brand 41 $181,392
Sofosbuvir-Velpatasvir Sofosbuvir/Velpatasvir Brand 11 $98,694
Xifaxan Rifaximin Brand 22 $58,948
Linzess Linaclotide Brand 76 $55,237
Motegrity Prucalopride Succinate Brand 29 $18,403
Budesonide Dr Budesonide Brand 35 $10,416
Mesalamine Generic 28 $7,942
Movantik Naloxegol Oxalate Brand 16 $6,354
Alosetron Hcl Generic 11 $4,365

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$124,696

Of which drugs: $104,025

Medicare patients

264

Average age 73

Services billed

4,933

114 women, 150 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 49%
Ischemic heart disease 25%
Depression 25%
Diabetes 22%
Chronic kidney disease 22%
COPD 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $192
  • GENZYME CORPORATION $162
$354 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $318
$318 — —
OMVOH
  • Lilly USA, LLC $293
$293 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $233
$233 22 —
SKYRIZI
  • AbbVie, Inc. $208
$208 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

510 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record